1[1]Wu A H B. Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins[J]. Scand J Clin Lab Invest,1999,59(Suppl 230): 74-82.
2[2]Panteghni M, Apple F S, Christenson R H, et al. Proposal from IFCC committee on Standadization of Markers of Cardiac Damage (C-SMCD): recommendation on use of biochemical markers of cardiac damage in acute coronary syndromes [J]. Scand J Clin Lab Invest, 1999,59(Suppl 230): 103-112.
3[3]Wu A H,Apple F S ,Gibler W B, et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery disease[J]. Clin Chem,1999,45: 1104-1121.
4[4]Alpert J S, Thygesen K, Antman E, et al. Myocardial infarction redefined:a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction[J]. J Am Coll Cardiol, 2000,36: 959-969.
5[5]Giri S,Waters D D,Wu A H B. Pathophysiology of acute coronary syndromes In: Card iac markers. Ed. Wu A H B. New Jersey:Humana Press Inc, 1998.21-44.
6[6]Winter R J, Fischer J, Bholasingh R, et al. C-reactive protein and cardiac troponin T in risk stratification:differences in optimal timing of tests early after the onset of chest pain[J]. Clin Chem,2000,46:1597-1603.
7[7]Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary, heart disease in initial healthy middle-aged men: results from the MONICA Augsburg Cohort Study, 1984 to 1992 [J]. Circulation, 1999, 99:237-242.
8[8]Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction [J].Circulation, 1999,99: 1671-1677.
9[9]Roberts W T, Sedrick R, Moulton L, et al. Evaluation of four automated high-sensitivity C-reactive protein methxts: implications for clinical and epidemiological applications[J]. Clin Chem, 2000,46:461-468.
10[10]Rifai N, Ridker P M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease [J]. Clin Chem,2001,47: 403-411.
4Heintzen MP, HeidlandU, Strauer BE. Management of patients with acute coronary syndrome:should we rely on cardiac marker? [J ]. J Interven Cardiol, 2000,13: 447 ～ 452
5Adams JE Brd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creative kinase the choice for the 1990s? [J].Circulation, 1993,88 (2): 750 ～ 763
6Christenson RH , Duh SH, Sanhai WR, et al. Characteristics of an albumin Cobalt binding test for assessment of acute coronary Syndrome patients: a multicenter Study[J]. Clin Chem, 2001,47: 464 ～ 470
7Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine Kinase-MB, myoglobin and troponin Ⅰ study[J ]. Circulation,2001,103(14): 1 832～1 837
8Azzazy HM, Christenson RH. Cardiac markers of acute coronary syndromes: is there a case for point of care testing? [J]. Clin Biochem,2002,35(1 ): 13～27
9Maynard SJ,Menown IB,Adger AA. Troponin T or troponin Ⅰ as cardiac markers in ischemic heart disease[J]. Heart, 2000,83 (4):371 ～373
10Klootwijk P, Hamm C. Acute coronary syndromes: diagnosis[J].Lancet, 1999,353(SⅡ ):10～15
